Association between adverse childhood experiences and health related quality of life in adult cancer survivors in the United States

• Published in: Journal of cancer survivorship
• Main Authors: Merkel, Emily C, Vandeleur, Daron M, Cheng, Xin, Littman, Alyson J, Baker, K Scott
• Format: Journal Article
• Language: English
• Published: United States 03-05-2024
• Subjects: Cancer-related pain; Health-related quality of life (HRQOL); Adverse childhood experiences (ACEs); Outcomes; Cancer survivorship
• ISSN: 1932-2259; 1932-2267; 1932-2267
• DOI: 10.1007/s11764-024-01603-5

The impact of adverse childhood experiences (ACEs) on health-related quality of life (HRQOL) is increasingly recognized, however, this has not been studied in cancer survivors in the United States. This study investigates if ACEs are associated with HRQOL in cancer survivors.
We conducted a cross-sectional analysis of the 2020 Behavioral Risk Factor Surveillance System from states that administered ACEs and Cancer Survivorship modules. Eligibility criteria included being a cancer survivor and not currently receiving cancer treatment. Primary exposure was number of ACEs (categorized as 0, 1-2, 3, or ≥ 4). Primary outcomes were self-reported measures of HRQOL including worse overall health and ≥ 14 unhealthy days (mentally or physically) per month. Mantel-Haenszel stratified analyses were performed and prevalence ratios were adjusted for age.
Of 5,780 participants, 62.0% were female and 67.8% were ≥ 65 years. Prevalence of worse overall health was 22.5% for individuals with no ACEs compared to 30.2% for 2-3 ACEs (aPR = 1.4, 95% CI 1.2, 1.5) and 38.5% for ≥ 4 ACEs (aPR = 1.7, 95% CI 1.5, 2.0). Prevalence of ≥ 14 unhealthy days was 18.1% with no ACEs compared to 21.0% for 1 ACE (aPR = 1.3, 95% CI 1, 1.3), 29.0% for 2-3 ACEs (aPR = 1.6, 95% CI 1.4, 1.8), and 44.8% for ≥ 4 ACEs (aPR = 2.2, 95% CI 2.0, 2.5).
Our study provides novel evidence of the association of multiple ACEs with higher prevalence of poor HRQOL in cancer survivors.
Screening for ACEs is warranted in all patients to guide targeted interventions to improve HRQOL and mitigate the impact of ACEs on HRQoL in cancer survivors.